Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma

Inclusion Criteria: * Histologically confirmed GBM, anaplastic astrocytoma, anaplastic oligoastrocytoma or anaplastic oligodendroglioma. * Disease progression (confirmed by MRI, PET or both) after radiation therapy * At least 28 days have elapsed since chemotherapy, major surgery or radiation therapy. * No other malignancy within 3 years except for non-melanomatous skin cancer or in situ cervical cancer. * Karnofsky performance score at least 70 * Platelet count ≥ 130/mm3. * Absolute neutrophil count ≥ 1500/mm3 * Calculated creatinine clearance greater than 45 mg/dl * AST \< 2 times the upper limit of normal * Bilirubin \< 1.5 times the upper limit of normal * Ability to give signed informed consent * Patients must be 18 years of age or older. Exclusion Criteria: * Prior intravenous or oral nitrosoureas (BCNU, CCNU) or prior VEGF targeted therapy including bevacizumab. No more than two prior chemotherapy regimens are allowed. Prior or current steroid use is allowed. * Evidence of CNS hemorrhage * Requirement for therapeutic anticoagulation * Any grade 3 or greater hemorrhage within the previous 28 days * Active inflammatory bowel disease * Inadequately controlled hypertension * Any prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association Grade II or greater congestive heart failure * History of myocardial infarction or unstable angina within 6 months prior to study enrollment * History of stroke or transient ischemic attack within 6 months prior to study enrollment * Significant vascular disease * Symptomatic peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment * Serious, non-healing wound, ulcer, or bone fracture * Proteinuria at screening * Pregnant (or lactating). Use of effective means of contraception in subjects of child-bearing potential * Prior organ transplantation * Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * Known acquired immune deficiency syndrome (AIDS) or HIV positive status